大多数公司认为,脱离药明康德可能会导致药物开发“大幅放缓”。//@ROY哥:回复@tu123456678:Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
$药明康德(SH603259)$ 哥的持仓成本经过几次T做到35了看看人气能不能带起医药板块了根据《纽约时报》报道,药明康德在美国医疗保健领域的参与程度之深,已远超国会的讨论。该国生物技术产业一些高层已明确反对这项法案,他们试图让国会意识到,突然「脱...